Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
about
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerKirsten Ras* oncogene: Significance of its discovery in human cancer researchAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerThe influence of subclonal resistance mutations on targeted cancer therapyNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Nanomedicine therapeutic approaches to overcome cancer drug resistancePrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesAcquired resistance to EGFR-targeted therapies in colorectal cancerCIViC databaseAn Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or NeuregulinColon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.A perspective on anti-EGFR therapies targeting triple-negative breast cancerMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveMolecular predictive markers in tumors of the gastrointestinal tractTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceClinical applications of liquid biopsies in gastrointestinal oncologyMechanisms of resistance to anti-EGFR therapy in colorectal cancerMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerMouse models of colorectal cancer as preclinical modelsKRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyExpression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer CellsMeasurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagentsCytohesins/ARNO: the function in colorectal cancer cellsBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersDetection of circulating tumor DNA in early- and late-stage human malignanciesTranslating neoadjuvant therapy into survival benefits: one size does not fit all.A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerThe quest to overcome resistance to EGFR-targeted therapies in cancer.Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibodyCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.
P2860
Q24563539-5527684C-0E8D-4848-82A4-A87FC639485AQ24604601-412E6089-946F-4C5B-B6DB-2C79FA3260EAQ26748924-075E840E-D6B7-4120-8E2D-6ADE7923A0E6Q26751212-C752F93A-5248-4777-B6B9-8BD6393C25F6Q26751344-DB10A93E-CF8E-48A6-BBFF-7EA5FCFE8D81Q26771952-C73038F0-46E5-426F-A12F-CB24252F5647Q26781693-B071B40F-CBB0-44D0-946A-C944F814CE6DQ26796348-09B47E01-32ED-4391-A21B-3F284FB3ABA7Q27011692-603A19D0-CE87-43AE-B9D4-138EE0602E9CQ27015224-33BB5F3A-86CC-4E05-B347-9380BBF2B66EQ27022741-82A6B2A8-AC13-4E93-9AB8-8D124CC14F38Q27612411-02BA184B-C4FE-40BD-A824-8AD3BA079FFFQ27679463-33C09476-8415-4CA2-AB8F-3ACDBF92D13AQ27853014-6C98D0CD-20A5-484C-9189-B34111AE0E0AQ28069867-C58E1E68-AB4D-4C0A-BF90-F9ADC4048A5AQ28070038-104E420E-10F7-42CE-B4BF-3F1CC2F9DF78Q28070583-32B7B102-D1DC-40DD-A401-1D04C826634AQ28071772-2C761DA2-5AC1-493A-8C50-D012816FB88FQ28073730-BCA45AE7-6789-4010-99DC-B1C8ABD98C46Q28074073-F813E474-71A4-4088-96E6-85C28FB6776CQ28076490-08931BCF-B702-436C-A0EF-CEB7945C4B14Q28077545-420391A2-5D0A-4F60-8B61-B153BC1A5CC7Q28081871-E335AABC-4DBC-4B99-8039-A66952445E6AQ28285473-D429A753-0A34-4027-9ADB-9ED0CF8AD6DCQ28534094-1EF5F2AE-6EC0-41D3-BDA2-9B5698ACBD8EQ28535487-9663D6AF-980F-46BF-8E5D-37121D9E9AEAQ28540770-B7A1BAC5-AAC4-4904-9CC6-2178C36BB5EBQ28543370-76CB61A2-3163-49D6-9A90-DEAB41B606B3Q28647615-B6A7D1D3-318B-4657-9456-20752FBC4630Q29395525-609CBDDA-CC5E-4C2E-B2B4-D73AC8E61F95Q29615778-FCC718CE-71E9-45F5-AE20-6DD8BF9CC98BQ30251738-19DEB759-8BFD-450C-AE32-41CC18A2D461Q30316105-56AD0E35-AEA3-4846-AA90-FA6D9CDDCF2DQ33356339-347BEC00-3D03-4BC7-8F89-25110A890AFFQ33601653-BEF7D941-9F27-482A-B56A-7606609576F1Q33624491-8ADDF104-A4AD-47ED-9EBA-FB9768A6563EQ33725976-34D1C2E6-E1A9-4F69-9875-88CDC41F860CQ33858231-4BAC2AD6-45B6-40F4-A9BB-634653ABEE6FQ33875560-60322CF0-5F49-4809-91AB-8F306558C0C8Q33895573-F99D2F12-B5AD-407B-8DED-70476453DF6E
P2860
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Identification of a mutation i ...... sistance in colorectal cancer.
@ast
Identification of a mutation i ...... sistance in colorectal cancer.
@en
Identification of a mutation i ...... sistance in colorectal cancer.
@nl
type
label
Identification of a mutation i ...... sistance in colorectal cancer.
@ast
Identification of a mutation i ...... sistance in colorectal cancer.
@en
Identification of a mutation i ...... sistance in colorectal cancer.
@nl
altLabel
Identification of a mutation i ...... esistance in colorectal cancer
@en
prefLabel
Identification of a mutation i ...... sistance in colorectal cancer.
@ast
Identification of a mutation i ...... sistance in colorectal cancer.
@en
Identification of a mutation i ...... sistance in colorectal cancer.
@nl
P2093
P2860
P4510
P50
P921
P3181
P356
P1433
P1476
Identification of a mutation i ...... sistance in colorectal cancer.
@en
P2093
Alba Dalmases
André Minoche
Beatriz Bellosillo
Clara Montagut
Francesc Bosch
Jeff Settleman
Joan Albanell
Joaquim Bellmunt
Manuel Gallen
Mar Iglesias
P2860
P2888
P3181
P356
10.1038/NM.2609
P407
P577
2012-01-22T00:00:00Z
P5875
P6179
1007295122